Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

被引：0
|
作者：
Lucia Del Mastro
Alessandra Fabi
Mauro Mansutti
Michele De Laurentiis
Antonio Durando
Domenico Franco Merlo
Paolo Bruzzi
Ignazia La Torre
Matteo Ceccarelli
Gbenga Kazeem
Paolo Marchi
Davide Boy
Marco Venturini
Sabino De Placido
Francesco Cognetti
机构：
[1] UO Sviluppo Terapie Innovative,IRCCS AOU San Martino
[2] Regina Elena Institute, IST
[3] S. Maria della Misericordia Hospital, National Institute for Cancer Research
[4] University of Naples Federico II,Division Oncology
[5] National Cancer Institute “Fondazione Pascale”,Department Oncology
[6] A.O.O.I. Regina Margherita S. Anna,Department of Endocrinology and Molecular and Clinical Oncology
[7] UO Epidemiologia Clinica,Department of Senology, Division of Breast Oncology
[8] Medical Department,IRCCS AOU San Martino
[9] Eli Lilly UK, IST
[10] S. Cuore – Don Calabria Hospital, National Institute for Cancer Research
来源：
BMC Cancer | / 13卷
关键词：
Metastatic breast cancer; Weekly schedule; 3-weekly schedule;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
    Heinemann, Volker
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Lerchenmueller, Christian
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Stauch, Martina
    Scheithauer, Werner
    Hielscher, Joerg
    Scholz, Michael
    Mueller, Sebastian
    Link, Hartmut
    Niederle, Norbert
    Rost, Andreas
    Hoeffkes, Heinz-Gert
    Moehler, Markus
    Lindig, Reinhard U.
    Modest, Dominik P.
    Rossius, Lisa
    Kirchner, Thomas
    Jung, Andreas
    Stintzing, Sebastian
    LANCET ONCOLOGY, 2014, 15 (10): : 1065 - 1075
  • [22] Preliminary results of a randomized phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer
    Hoelzer, K. L.
    Brufsky, A.
    Hainsworth, J.
    Beck, J. T.
    Whorf, R.
    Keaton, M.
    Kroener, J.
    Krill-Jackson, E.
    Hu, S.
    Bromund, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial
    Blohmer, J. -U.
    Schmid, P.
    Hilfrich, J.
    Friese, K.
    Kleine-Tebbe, A.
    Koelbl, H.
    Sommer, H.
    Morack, G.
    Wischnewsky, M. B.
    Lichtenegger, W.
    Kuemmel, S.
    ANNALS OF ONCOLOGY, 2010, 21 (07) : 1430 - 1435
  • [24] First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study
    Allouache, D
    Gawande, SR
    Tubiana-Hulin, M
    Tubiana-Mathieu, N
    Piperno-Neumann, S
    Mefti, F
    Bozec, L
    Genot, JY
    BMC CANCER, 2005, 5 (1)
  • [25] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
    Hutson, Thomas E.
    Lesovoy, Vladimir
    Al-Shukri, Salman
    Stus, Viktor P.
    Lipatov, Oleg N.
    Bair, Angel H.
    Rosbrook, Brad
    Chen, Connie
    Kim, Sinil
    Vogelzang, Nicholas J.
    LANCET ONCOLOGY, 2013, 14 (13): : 1287 - 1294
  • [26] A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer
    Wang, Biyun
    Sun, Tao
    Zhao, Yannan
    Wang, Shusen
    Zhang, Jian
    Wang, Zhonghua
    Teng, Yue-E
    Cai, Li
    Yan, Min
    Wang, Xiaojia
    Jiang, Zefei
    Pan, Yueyin
    Luo, Jianfeng
    Shao, Zhimin
    Wu, Jiong
    Guo, Xiaomao
    Hu, Xichun
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [27] First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study
    Djelila Allouache
    Sulochana R Gawande
    Michele Tubiana-Hulin
    Nicole Tubiana-Mathieu
    Sophie Piperno-Neumann
    Fawzia Mefti
    Laurence Bozec
    Jean-Yves Genot
    BMC Cancer, 5
  • [28] A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer
    Biyun Wang
    Tao Sun
    Yannan Zhao
    Shusen Wang
    Jian Zhang
    Zhonghua Wang
    Yue-E Teng
    Li Cai
    Min Yan
    Xiaojia Wang
    Zefei Jiang
    Yueyin Pan
    Jianfeng Luo
    Zhimin Shao
    Jiong Wu
    Xiaomao Guo
    Xichun Hu
    Nature Communications, 13
  • [29] Randomized, open-label, phase III, multicenter trial comparing AT (doxorubicin, paclitaxel) versus FAC (5-fluorouracil, doxorubicin, cyclophosphamide) as first-line treatment for patients with metastatic breast cancer
    Tjulandin, SA
    SEMINARS IN ONCOLOGY, 1999, 26 (06) : 10 - 10
  • [30] Final results of first-line weekly paclitaxel plus gemcitabine in metastatic breast cancer (MBC): an AERO phase II trial
    Mousseau, M.
    Serin, D.
    Goubely-Brewer, Y.
    Petit, T.
    Priou, F.
    Zelek, L.
    BULLETIN DU CANCER, 2007, 94 (06) : 569 - 570
12345